TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07787182: A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's

Sponsor: Eli Lilly and Company · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 68 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,875,856

Rescue Site Savings

+$1,899,648

Unlock Full NCT07787182 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07787182 Rescue Dossier →